Innovative solutions from Industry 4.0
10th June 2019 | 10:00 am EST | Michael May, President and CEO, CCRM at Centre For Commercialization Of Regenerative Medicine and Philip G. Vanek, PhD, General Manager, Cell and Gene Therapy Strategy at GE |BOOK FREE SEAT
- Potential to providing real-time visibility
- Control across complex cell and gene therapy supply chains
- How can industry 4.0 drive the industry towards increased industrialization?
Presneted By Michael May, President and CEO, CCRM at Centre For Commercialization Of Regenerative Medicine
Michael May is President and Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies and launches new companies by supporting both academic and industry activities in the field of regenerative medicine, including cell and gene therapy. With a staff of 85, a network of academic members, 100 industry partners, dedicated funding and facilities to develop technologies, manufacture cell product and incubate companies, CCRM is generating health and economic benefits for its stakeholders. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.
Michael sits on a number of boards and advisory committees including: the Centre for the Commercialization of Antibodies and Biologics (CCAB); the Entrepreneurship Leadership Council at the University of Toronto; the TO Health! Human & Science Steering Committee; the Cell and Gene Therapy Insights, Editorial Advisory Board; the Industry Committee of the International Society for Stem Cell Research (ISSCR); and the Executive Committee, Alliance for Regenerative Medicine (ARM). He is the Chairman of the start-up company: ExCellThera Ltd.
Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
Sponsored by GE Healthcare
At GE Healthcare’s Life Sciences, we accelerate precision medicine by helping researchers, pharmaceutical companies, and clinicians discover and make new medicines and therapies. We provide expertise, technology and services for a wide range of areas within the life sciences industry, including the manufacture of contrast agents for diagnostic imaging, basic research of cells and proteins, and technologies that enable large-scale manufacturing of vaccines, biologics, and cell therapy.
The emergence of cell therapy as a treatment for challenging diseases, including cancer, is rapidly changing the healthcare landscape. Our Cell Therapy business provides the tools, technology and processes to enable customers from pharmaceutical manufacturing as part of our Cell Processing segment, to clinicians and technicians in our Cell Banking and Point of Care business segments. We are investing in the field for the long-term, and partnering with pharma, biotech and clinical researchers. GE brings expertise in quality, global distribution, R&D, and regulatory that will transform cell therapy from small-scale treatment to a globally-accessible personalized medicine.
Followed by Philip G. Vanek, PhD, General Manager, Cell and Gene Therapy Strategy at GE
Prior to joining GE Healthcare Life Sciences, Phil was head of business development for cell therapy at Lonza’s Pharmaceutical division. Later, as their head of Innovation, he helped drive new technology initiatives focused on cell, protein, and viral therapeutic manufacturing. Phil’s career has included a number of innovation, business, and market development roles at Becton Dickinson, Invitrogen, and Life Technologies, and two start-up biotechnology companies in the Washington, DC area. Additionally, Phil was an instructor for Johns Hopkins University Advanced Academic Programs, teaching Biotechnology Marketing for several years while working at BD and Lonza. Phil received his PhD in Biochemistry and Molecular Biology from Georgetown University Medical Center and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology and the Hollings Cancer Center in Charleston, South Carolina. Phil is an active board member of the Alliance for Regenerative Medicine and the ARM Foundation, as well as the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto. Phil has published a number of industry position pieces and serves on the Editorial Board of Cell and Gene Therapy Insights.